WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Rim Zakaria Alkasem*, Suzanne Alshemali and Firas Hussein

ABSTRACT

Determination of prognostic factors in patients with acute leukemia is crucial in reducing intensive chemotherapy, decreasing economic costs, and improving the outcome of the patients. We conducted this study to determine the prognostic value of CD10 expression in B-acute lymphoblastic leukemia (studying the relationship between CD10 expression and therapeutic response, overall survival, and event-free survival). Also, we want to study the combined expression of CD10 and CD34, and the effect on overall survival and event-free survival. A retrospective study included 119 patients from 1st January 2010 to 31 December 2016. We monitored the patients until 1st December 2019. In B-acute lymphoblastic leukemia, expression of CD10 was 81.5%. Most patients whose Blasts had CD10+ were children and standard risk stratification. In contrast, patients with CD10- had significantly an increased incidence of B symptoms, fever (infection), and cerebrospinal fluid infiltration. We found that complete remission after 4 weeks and after 18 months of starting treatment was significantly higher in CD10+ patients than CD10- patients and in CD10+ and/or CD34+ patients than CD10-CD34- patients. Death was significantly higher in patients with CD10- than CD10+. The median survival rate was higher in patients with CD10+ than CD10- and in CD10+ and\or CD34+ patients than CD10-CD34- patients but without statistical significance. Our findings suggest that CD10 expression and the combined expression of CD10 and CD34 have a favorable prognosis in patients with B-acute lymphoblastic leukemia.